Please assess the completion status of the following clinical trial:

Trial Title: Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed breast cancer~  * Locally advanced or inflammatory disease~    * T4a-d, any N, M0 OR~   * Any T, N2 or N3, M0~   * Large operable T2 or T3 tumors~* No bilateral breast cancer~* Frozen tumor sample available~  * 1 incisional biopsy OR~ * 2 trucut biopsies from a 14G needle~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* 70 and under~Sex:~* Female~Menopausal status:~* Not specified~Performance status:~* WHO 0-1~Life expectancy:~* Not specified~Hematopoietic:~* Neutrophil count greater than 1,500/mm\^3~* Platelet count greater than 100,000/mm\^3~Hepatic:~* Bilirubin less than 1.2 mg/dL~* SGOT less than 60 IU/L~Renal:~* Creatinine less than 1.35 mg/dL~Cardiovascular:~* LVEF normal by echocardiography or MUGA~Other:~* No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* No serious uncontrolled medical condition~* No uncontrolled psychiatric or addictive disorders~* Not pregnant or nursing~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy~Surgery:~* See Disease Characteristics

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- non taxane based chemotherapy (Type: ACTIVE_COMPARATOR): either FEC 100 or Canadian CEF or Tailored FEC for 6 cycles
- taxane based chemotherapy (Type: EXPERIMENTAL): Docetaxel for 3 cycles followed by Epirubicin/Docetaxel for 3 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).